GlassScriptPhysician profile
Brian W Zagol
NPI 1902901556
$3,434.60
in general payments reported to CMS, 2019-2025
34 companies · $858 in 2025
The $858 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $203 · 2021: $421 · 2022: $282 · 2023: $514 · 2024: $504 · 2025: $858.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,876.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,875.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $473.88 | 2019-2025 | Watchman Flx, Cds - Mct/Cem Monitoring |
| Novartis Pharmaceuticals Corporation | $425.58 | 2020-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $365.54 | 2019-2025 | Lifevest |
| Medtronic, INC. | $262.43 | 2021-2025 | Ffrangio, Onyx Frontier, Venaseal |
| Astrazeneca Pharmaceuticals LP | $235.81 | 2020-2025 | Brilinta, Farxiga, Lokelma |
| Amgen INC. | $213.72 | 2019-2025 | Repatha, Repatha |
| Novo Nordisk INC | $154.99 | 2019-2025 | Wegovy |
| Medtronic Vascular, INC. | $150.38 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $136.70 | 2020-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $105.44 | 2019-2024 | Camzyos, Eliquis |
| Pfizer INC. | $98.77 | 2019-2025 | |
| Irhythm Technologies, INC. | $91.99 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.26 | 2021-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $50.06 | 2021-2023 | Verquvo |
| Kiniksa Pharmaceuticals International, Plc | $46.24 | 2024 | Arcalyst |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $39.21 | 2023-2024 | Cardiomems, Mitraclip |
| Esperion Therapeutics, INC. | $39.01 | 2021-2024 | Nexletol |
| Bayer Healthcare Pharmaceuticals INC. | $37.62 | 2021-2025 | |
| Shockwave Medical, INC | $37.40 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Penumbra, INC. | $36.76 | 2025 | Indigo System |
| Actelion Pharmaceuticals US, INC. | $35.32 | 2023 | Opsumit, Uptravi |
| Baxter Healthcare | $33.63 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor |
| W. L. Gore & Associates, INC. | $33.58 | 2019 | |
| Scpharmaceuticals INC. | $32.41 | 2025 | |
| Cvrx, INC. | $27.89 | 2022 | |
| Inspire Medical Systems, INC. | $27.55 | 2025 | Inspire |
| Philips North America LLC | $26.51 | 2025 | Igt Devices Systems Undivided |
| Inari Medical, INC. | $25.54 | 2022 | |
| Getinge USA Sales, LLC | $24.05 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $22.18 | 2023 | Arcalyst |
| Vifor Pharma, INC. | $20.93 | 2019 | |
| Bardy Diagnostics, INC. | $20.00 | 2022 | |
| Bard Peripheral Vascular, INC. | $19.15 | 2024 | Venclose Maven Catheter |
| Lexicon Pharmaceuticals, INC. | $19.07 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Zagol listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.